A 12-week treatment of the fermented soy germ-based nutritional supplement containing S-equol significantly lowered hemoglobin A1c (HbA1c), LDL cholesterol and improved vascular stiffness, all factors that occur as part of metabolic syndrome, according to a first-of-its-kind peer-reviewed study reported in a poster at the Women's Health 2012 annual meeting. "This study is the first to provide evidence that a daily supplement of soy-based S-equol favorably change metabolic syndrome risk factors, particularly in women. Because not all individuals have the ability to produce S-equol naturally after eating soy, the study results are very interesting and warrant examination in future studies, " said Belinda H. Jenks, Ph.D., coauthor of the study and director of Scientific Affairs & Nutrition Education at Pharmavite LLC, an U.
Giving a pre-hospital shot of adrenaline, also known as epinephrine, to someone with cardiac arrest may help restore circulation in the short term, but could do them harm in the long term, according to a large new study from Japan published in JAMA on Wednesday that suggests it may be a case of saving the heart at the cost of the brain. When someone has a cardiac arrest, their heart stops pumping blood, and if they don't receive cardiopulmonary resuscitation (CPR) within minutes, they will probably die. When emergency services personnel attend such a casualty, they sometimes give them a shot of epinephrine to help get the heart started, before they get to hospital. But researchers Dr Akihito Hagihara, of the Department of Health Services Management and Policy at Kyushu University Graduate School of Medicine, and colleagues, write in their background information that the effectiveness of epinephrine use before hospital arrival has not been established.
Researchers have clinically applied the first point-of-care genetic test in medicine. Results from the study confirm that the test successfully identifies the CYP2C19*2 allele, a common gene mutation linked to higher rates of major side effects in patients receiving clopidogrel following percutaneous coronary intervention (PCI), thus preventing complications in those patients. The study, which has been conducted by Dr Derek Y F So at the University of Ottawa Heart Institute in Ottawa, Canada, and his team is published Online First in The Lancet. Following PCI, the standard care for patients commonly consists of aspirin and clopidogrel to reduce the risk of blood clot formation, however, this dual antiplatelet therapy results in many patients becoming vulnerable to major adverse cardiovascular events.
Birth control pills containing drospirenone are linked to a higher risk of stroke, the FDA (Food and Drug Administration) has announced today. The Agency explains that it has completed its review of recent epidemiologic studies. Drospirenone, a synthetic version of progesterone, a female hormone, is often referred to as progestin. The FDA concluded that birth control pills that contain drospirenone are linked to a higher blood clot risk, compared to other pills which contain progestin. Drospirenone-containing contraceptive pills will have details regarding this risk added to their labels. It is important that patients discuss blood clot risks with their doctors before deciding upon which birth control method to adopt, the FDA stressed. Also, doctors should weigh the risks versus benefits of birth control medications that contain drospirenone, including blood clot risks, before prescribing these contraceptives.
Results of a meta-analysis published Online First by Archives of Internal Medicine, indicate that there is not enough evidence that omega-3 fatty acid supplements have a secondary preventive effect against overall cardiovascular events among individuals who have a history of heart disease. According to the researchers, results from some earlier trials indicate that omega-3 fatty acid supplements are effective in the secondary prevention of cardiovascular disease (CVD). However, the evidence remains inconclusive. In order to analyze the link between the omega-3 supplements such as, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), and the risk of developing heart disease among individuals with a history of CVD, Sang Mi Kwak, M.D., of the Center for Cancer Prevention and Detection, Republic of Korea, and colleagues, conducted a meta-analysis of 14 randomized, double-blind, placebo-controlled trials, conducted between June 1995 and November 2010.